Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 3/20 | 1.00 |
| ▸ | ABCC1 | P33527 | 2/20 | 1.00 |
| ▸ | STS | P08842 | 3/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.77 |
| ▸ | ESR1 | P03372 | 5/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | PGR | P06401 | 2/20 | 0.74 |
| ▸ | AR | P10275 | 2/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | ATM | Q13315 | 2/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.69 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392632 | 1.00 | ABCC4 (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL30471686 | 1.00 | ABCC4 (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL232796 | 1.00 | ABCC4 (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| E2Mate SCHEMBL5151234 | 0.91 | STS (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| E2Mate SCHEMBL5165269 | 0.91 | STS (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL2291502 | 0.91 | KDM4E (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL19121776 | 0.91 | ABCC4 (0.83) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL21033841 | 0.91 | ABCC4 (0.83) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL20634998 | 0.91 | ABCC4 (0.83) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL4966962 | 0.91 | KDM4E (1.00) | ABCC4ABCC1STSKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2317995-B1 | INHBITORS OF MRP4 AND AGENTS STIMULATING MRP4 ACTIVITY FOR THE TREATMENT OF CARDIAC DISORDERS | INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) (FR) | 2016-12-07 | — | — | EP | claimed |
| WO-2013172969-A1 | METHODS AND COMPOSITIONS FOR TREATING TRAUMA-HEMORRHAGE USING ESTROGEN AND DERIVATIVES THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2013-11-21 | — | — | WO | claimed |
| EP-1898894-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2008-03-19 | — | — | EP | claimed |
| WO-2006134022-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | WO | claimed |
| US-20060286041-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | US | claimed |
| CN-1119929-C | Pig embryo regulation factor and its preparing process and application | XU LIREN (CN) | 2003-09-03 | — | — | CN | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2006111549-A1 | DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| EP-1212618-A4 | EFFECT OF STEROIDS ON NMDA RECEPTORS DEPENDS ON SUBUNIT COMPOSITION | UNIV BOSTON (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6623933-B1 | Contacting with neurotransmitter recognition site ligand in the presence and absence of a steroid-based molecule; chimeric isoform; use in treating neurological disorders including ischemic stroke, epilepsy and schizophrenia | TRUSTEES OF BOSTON UNIVERSITY | 2003-09-23 | — | — | US | disclosed |
| CN-1119929-C | Pig embryo regulation factor and its preparing process and application | XU LIREN (CN) | 2003-09-03 | — | — | CN | disclosed |
| EP-1212618-A1 | EFFECT OF STEROIDS ON NMDA RECEPTORS DEPENDS ON SUBUNIT COMPOSITION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016601-A1 | EFFECT OF STEROIDS ON NMDA RECEPTORS DEPENDS ON SUBUNIT COMPOSITION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-1998004578-A1 | METHOD OF PRODUCING 3-SULFANATO-OXY-ESTRA-1,3,5(10)-TRIEN DERIVATES (I) | SCHERING AG (DE) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ABCC4 1339/4885ABCC1 662/4885STS 4420/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ABCC4 11/4885ABCC1 15/4885STS 1695/4885 |
| US-20060286041-A1 | MRP IV INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | ABCB1, ABCC4, ABCC1 | ABCC4 2/4885ABCC1 3/4885STS 2939/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | ABCC4 1339/4885ABCC1 662/4885STS 4420/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | ABCC4 11/4885ABCC1 15/4885STS 1695/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ABCC4 1339/4885ABCC1 662/4885STS 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.